Elderly have poor prognosis after recovery in long-term acute care hospitals
Most patients die within 5 years and spend two-thirds of remaining life as an inpatient.
Most patients die within 5 years and spend two-thirds of remaining life as an inpatient.
Article written by Tom Collins. Interview by Esther Drain. Meletios Dimopoulos, MD, professor and chairman of clinical therapeutics at the University of Athens and a long-time expert in… read more.
Prof Peter Johnson (Southampton, UK) discusses where there is consensus and controversy in the management of HL in 2019, as well as talking about the key takeaways from his… read more.
Autologous stem cell transplantation (ASCT) remains the standard of care option for those patients with newly-diagnosed multiple myeloma (MM) who are eligible for and able to tolerate… read more.
Professor Sagar Lonial (Atlanta, USA) opened the UKMF by discussing the latest evidence in the management of myeloma, with comment from session chair Professor Gordon Cook (Leeds, UK).
Professor Graham Jackson (Newcastle, UK) gives an overview of his presentation on real world management of myeloma patients in the UK, with comments from Professor Sagar Lonial (Atlanta, USA). Professor Jackson… read more.
Professor Gordon Cook (Leeds, UK), Professor Guy Pratt (Birmingham, UK) and Professor Graham Jackson (Newcastle, UK) discuss the need for maintenance in the up-front setting for UK patients and the new data on… read more.
IBD is still mainly a phenomenon of the Western world, but the incidence is increasing steeply in newly industrialised countries where the population is undergoing rapid urbanisation…
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of lymphoid malignancies that often fails to respond to standard of care treatment,1-3 and the need for new therapies is… read more.
Article by Maria Dalby. Interviews by Hannah Chatfield Achieving the ultimate goals of maintaining cure and minimising long-term toxicity in Hodgkin lymphoma (HL) requires individualised therapy based on… read more.
Dr Johan Burisch (Denmark) reviews data he presented on the cost saving effect of biological therapy in patients with IBD.
A randomised, controlled screening trial for lung cancer involving almost 16,000 people in the Netherlands and Belgium found that CT screening produced a 26% reduction in lung cancer… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.